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Abstract
Enhanced osteogenic potential by inhibiting 
LHX8 overexpression-associated ID1 in 
human dental pulp stem cells
Ji-Youn Kim 
Program in Oral and Maxillofacial Surgery, Department of Dental Science, 
Graduate School, Seoul National University 
(Directed by Professor Pill-Hoon Choung)
LIM homeobox 8 (LHX8) encodes a transcription factor protein that is 
necessary for embryonic development of craniofacial tissues including bone 
and teeth. Previous animal studies suggest that LHX8 may have a role in 
osteogenesis, but the finding requires further supporting evidence in human 
dental pulp cells which possess the osteogenic ability. A lentiviral system was 
utilized in this study to overexpress LHX8 in human dental pulp stem cells 
(DPSCs) and the effect of overexpressed LHX8 on osteogenesis was analyzed. 
LHX8 overexpression did not modulate proliferation, migration, nor 
the angiogenic property of DPSCs. On the other hand, the osteogenic 
differentiation ability of DPSCs was attenuated, demonstrated by decreased 
alkaline phosphatase activity and calcium accumulation. cDNA microarray 
analysis showed that genes associated with protein binding were differentially 
expressed in osteodifferentiated DPSCs. There were 38 differentially 
expressed genes (DEGs) which were common both in response to 
osteodifferentiation and LHX8 overexpression, and there were grouped into 
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two clusters. Each cluster responded in an opposite way, i.e. upregulated
during osteodifferentiation but downregulated by LHX8 overexpression or 
vice versa, supporting an anti-osteogenic role of LHX8. In order to develop a 
molecular approach to promote osteogenesis of DPSCs, genes downregulated 
in control cells but upregulated in LHX8 cells during osteodifferentiation were 
screened. Chemical inhibitors were treated to their protein products to see if 
osteodifferentiation of DPSCs were enhanced. ML323, which target DNA-
binding protein inhibitor ID-1, promoted osteodifferentiation of DPSCs.
In summary, an anti-osteogenic effect of LHX8 was confirmed in this 
study by a LHX8 overexpressing DPSCs model. An anti-osteogenic gene ID1
was discovered. Finally, it was demonstrated that by inhibiting DNA-binding 
protein inhibitor ID-1, osteogenesis was promoted in human DPSCs.
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GENERAL INTRODUCTION
LIM homeodomain proteins are a family of transcription factors [1]. Among 
them, LHX8 may play a role in osteogenesis [2-5], but the finding requires 
further supporting evidence in human cells. Mesenchymal stem cells (MSCs) 
reside in various parts of adult tissues and organs [6]. Among the subtypes of 
MSCs, dental pulp stem cells (DPSCs) possess osteogenic characteristics [7], 
and less invasive to isolate [8, 9, 10]. Therefore, DPSCs are good sources of 
studying the role of LHX8 in osteodifferentiation. 
Craniofacial bone defects caused by osteomyelitis, malignancy or 
traumatic conditions require bone reconstruction [11, 12]. Autologous bone 
grafting is the traditional approach for reconstruction due to the craniofacial 
bone defects [11-13]. However, there are limitations for wide-spread use [14, 
15]. Bone morphogenic proteins (BMPs), are often used in clinics to aid bone 
reconstruction, but there are also drawbacks [16, 17]. There is an urgent need 
for the development of osteogenic agents which may aid bone regeneration.
In this study, LHX8 overexpression on DPSCs has revealed the anti-
osteogenic properties of the gene. Using the LHX8 DPSCs model, druggable 
LHX8-associated genes were screened and functional inhibitors were treated 
to find compounds with the osteogenic property. These findings may lead to 








LIM homeodomain proteins are a family of transcription factors which in 
mammals 12 subtypes have been discovered [1]. LHX8, or formerly L3 and 
LHX7, is a member of the LIM homeodomain proteins and is expressed in the 
craniofacial tissues during the development process [2]. The molecular 
function of LHX8, often working in combination with its paralogous gene 
LHX6, has been proposed mainly by studies using mouse models. 
Homozygous deletion or mutation of LHX8 leads to cleft palate development 
in mice [3]. Lhx6/8 double knockout mice have defects of the cranial skeleton 
and die shortly after birth [4]. Failure of dental mesenchyme differentiation 
and tooth formation was observed in the Lhx6/8 double knockout mouse [5]. 
These studies suggest that LHX8 may play a role in osteogenesis, but the 
finding requires further supporting evidence in human cells. 
MSCs reside in various parts of adult tissues and organs, can be 
isolated and expanded easily, and possess the ability to differentiate into 
various tissue types including the bone [6]. Among the subtypes of MSCs, 
DPSCs PBScomparable osteogenic characteristics to bone marrow stem cells 
(BMSCs), the most widely studied MSCs [7]. DPSCs can be isolated and 
expanded from dental pulp either from permanent teeth removed for 
orthodontic reasons or third molar teeth for prophylactic reasons [8], whereas 
an invasive surgical intervention is necessary to obtain BMSCs [9]. 
Furthermore, the osteogenic potential of DPSCs was superior to other stromal 
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cells of dental origin, the gingival fibroblasts [10]. Therefore, DPSCs are good 
sources of studying the role of LHX8 in osteodifferentiation. 
In this study, DPSCs were isolated and expanded from human third 
molar teeth. LHX8 was overexpressed in DPSCs using a lentiviral system. The 
functional changes that occurred in LHX8 overexpressing DPSCs were 
observed using various functional assay skills, including quantitative PCR, 




1. Human dental pulp stem cells
Human third molars were collected from three healthy young males and a 
female (18–25 years old) under the protocol approved by the Institutional 
Review Board of the Seoul National University Dental Hospital, Seoul, South 
Korea (IRB No. 05004). Dental pulps were gently separated from extracted 
teeth and the separated tissues were digested in a solution of 3 mg/mL 
collagenase type I (Worthington Biochem, Freehold, NJ, USA) and 4 mg/mL 
dispase (Boehringer, Mannheim, Germany) for 1 hour at 37°C. Single-cell 
suspensions were obtained by passing the cells through a 70 μm strainer 
(Falcon BD Labware, Franklin Lakes, NJ, USA) and were cultured in the 
alpha-modification of Eagle’s medium (aMEM, Welgene, Daegu, Korea) 
supplemented with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, 
USA), 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin 
(Invitrogen) and incubated at 37°C in 5% CO2. The medium was changed 
after the first 24 hours and then every 3-4 days. All primary cells used in this 
study were in passage 2-5. Cells were imaged using an Olympus CKX53 
microscope.
2. Flow cytometric analysis
To characterize the immunophenotype of DPSCs, the expression of 
mesenchymal stem cell (MSC)-associated surface markers at passage 4 was 
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analyzed by flow cytometry. Briefly, cells in their third passage (1.0 x10e6
cells) were fixed with 3.7% paraformaldehyde for 10 minutes and 
resuspended in phosphate-buffered saline (PBS) containing 1% bovine serum
albumin (BSA, ICN Biomedicals, Aurora, OH, USA) for 30 minutes for 
blocking. Cells were then incubated with specific antibodies for CD34, CD13, 
CD90, or CD146 at 4 °C for 1 hour, followed by incubation with fluorescence 
secondary antibodies at room temperature for 1 hour. All antibodies were 
purchased from BD Biosciences (San Jose, CA, USA). The percentage of 
CD13-, CD90-, and CD146-positive and CD34-negative cells was measured 
with a FACSVerse flow cytometer (Becton Dickinson, San Jose, CA, USA).
3. Lentivirus transduction 
The full-length coding sequences of LHX8 were amplified by PCR from 
DPSCs. PCR amplification products were cloned into the pCDH-CMV-MCS-
EF1-copGFP lentiviral vector (System Biosciences, Mountain View, CA, 
USA) and packaged by co-transfection with psPAX2 and pMD2.G plasmids 
with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in HEK293FT 
(Invitrogen, Carlsbad, CA, USA) cells. The virus was harvested and 
concentrated by ultracentrifugation 48 hours later. For LHX8 overexpression, 
passage 2 DPSCs were treated with different multiplicities of infection (MOIs)
of lentivirus for 24 hours and examined for green fluorescent protein (GFP)
expression after 3 days. MOIs that generated at least 95% of GFP-positive 
cells were chosen for further culture (MOI 30 for control, MOI 100 for LHX8). 
These cells were at least twice passaged before used for experiments. 
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HEK293FT cells were cultured in Dulbecco's Modified Eagle’s Medium 
(DMEM, Welgene, Seoul, Korea) media with 10% FBS.
4. Western blotting 
LHX8 overexpressing DPSCs and control DPSCs were cultured in 100 mm 
dishes until approximately 80% confluent. Cells were washed twice with PBS 
and detached from the culture plate using a cell scraper. Cells were lysed on 
ice for 15 minutes with radio-immuno-precipitation assay (RIPA) buffer 
(Thermo Scientific, Rockford, IL, USA), which contains 1% proteinase 
inhibitors. The samples were loaded onto a 10% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel and subjected to electrophoresis on ice. The 
proteins resolved were transferred onto nitrocellulose membrane for 1 hour
and blocked for 1 hour at room temperature with 5% skim milk. The 
membranes were incubated overnight at 4°C with the primary antibodies. 
Anti-beta actin and anti-LHX8 were obtained from Abcam (Abcam, 
Cambridge, MA, USA). The membranes were washed in Tris-buffered saline-
Tween 20 (TBST) and incubated with the secondary antibody. Detection was 
done in the dark using enhanced chemiluminescence solution (GE healthcare, 
Chicago, IL, USA).
5. Cell proliferation assay
Cell proliferation was measured using the tetrazolium salt WST-1 assay kit 
(Clonetech, Palo Alto, CA, USA). Briefly, DPSCs (1.0×10e3 cells/well) were 
seeded in 96-well plates and were incubated in 5% CO2 at 37°C for 5 days. 
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Every day, the WST-1 dye solution was added and cells were incubated in 5% 
CO2 at 37°C for 2 hours until the stop solution was added to the cultures to 
stabilize the formazan product. Each condition was prepared in triplicate, and 
reactions were assessed using an enzyme-linked immunosorbent assay 
(ELISA) reader at optical density (OD) 450nm.
6. Cell migration assay
Migration of DPSCs was observed using the Transwell® culture insert with 8 
μm pores (Corning, Grand Island, NY, USA). After one-day serum starvation 
(0.1%), DPSCs were loaded onto the insert with low serum medium (0.1%). 
The lower chamber was filled with complete growth medium with 10% FBS 
to facilitate migration through pores. Following 24 hours incubation, 
remaining cells in the upper chamber were removed using a cotton swab and 
cells in the bottom layer of the Transwell® were fixed with 4% 
paraformaldehyde and stained with 0.1% crystal violet solution. After 
microscopic images were obtained, crystal violet stained cells were quantified 
by solubilizing them using 0.1% SDS.
7. Real-time cell migration assay 
The real-time analysis of cell migration assay was performed using the 
xCELLigence DP Real Time Cell Analyzer and CIM-16 plates with 8 μm pore 
membranes. The bottom electrodes of the CIM-16 plates were coated with 0.2% 
gelatin and incubated in a laminar airflow chamber for 30 minutes. DPSCs 
were loaded onto the upper compartments with low serum medium (0.1%). 
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The lower side was filled with complete growth medium with 10% FBS to 
facilitate migration. The impedance data, reported as cell index and 
proportional to the area of the bottom electrodes covered by migrated cells, 
were collected every 15 minutes. For easy visualization, 10-time points during 
24 hours of observation were depicted.
8. Angiogenesis assay
To measure the angiogenic property of DPSCs, a tube formation assay was 
performed. The inner wells of a μ-slide (Ibidi, Planegg, Germany) were 
coated with Matrigel® basement membrane matrix (BD Biosciences, Franklin 
Lakes, NJ). Human umbilical vein endothelial cells (HUVECs) were seeded 
on top of the Matrigel® with 48 hours conditioned medium of DPSCs. The 
cultures were incubated for 16 hours before microscopic images of tubular 
structures were taken. The numbers of tubes were manually counted for 
quantification. HUVECs were cultured in M200 media supplemented with 
LVES (Thermo, A1460801)
9. Osteodifferentiation
For osteogenesis, the DPSCs were grown with complete culture media until 
confluence. Then the medium was changed to an osteogenic differentiation 
medium with 50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, and 
100 nM dexamethasone (all from Sigma-Aldrich) for up to 4 weeks. 
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10. Real-time reverse transcription–polymerase chain reaction (real-time 
RT-PCR)
To evaluate gene expression levels in osteodifferentiated DPSCs, LHX8
overexpressed cells or control cells were cultured under an osteogenic 
differentiation condition. Total RNA was prepared using an RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. 
cDNA was synthesized from 1 μg of total RNA using reverse transcriptase 
(Superscript II Preamplification System; Invitrogen, Carlsbad, CA, USA). RT-
PCR was conducted as on an ABI7500 thermal cycler. The expression levels 
of genes were calculated using the relative quantification method. The
specific primer-probe sets used for RT-PCR are listed in Table 1.
Table 1. Primer-probe information
Gene Accession Company Product no.
GAPDH NM_002046 IDT Hs.PT.39a.22214836
ALPL NM_000478.6 Thermo Hs01029143_m1
COL1A1 NM_000088.3 Thermo Hs00164004_m1
IBSP NM_004967.3 Thermo Hs00913377_m1
RUNX2 NM_001015051.3 Thermo Hs01047975_m1
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11. Alkaline phosphatase activity measurement
Osteodifferentiated DPSCs were fixed with 4% paraformaldehyde and stained 
for alkaline phosphatase (ALP) activity with 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium (BCIP/NBT) color development substrate 
(Promega, Madison, WI, USA) on differentiation day 7. After the acquisition 
of microscopic images, stained ALP substrate was solubilized with SDS 
solution with 0.1M hydochloride for quantification.
12. Calcium accumulation measurement
Accumulation of mineral nodules was detected by staining with 2% Alizarin 
red S staining at pH 4.2 (Sigma-Aldrich, St Louis, MO, USA). For the 
destaining procedure to measure the calcium content, 3 mL of 10 mM sodium 
phosphate in 10% acetylpyrimidium (pH 7.0, Sigma-Aldrich) solution was 
added to each stained well and incubated at room temperature for 15 minutes. 
The destained sample was transferred to a 96-well plate and the absorbance 
was measured at 562 nm.
13. Statistical analysis
Statistical analysis was performed using Prism software (GraphPad Software, 
San Diego, CA, USA). Comparison between two groups was made with 
Student’s t-test. Significance was defined as P≤0.05. Values in each graph 
represent mean±standard deviation. All assays were performed at least thrice 
and representative data are presented.
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RESULTS
DPSCs were successfully isolated and expanded from surgically removed 
human third molar teeth.
To explore roles of LHX8 in craniofacial calcifying tissues, human dental pulp 
stem cells were isolated and expanded in vitro. These cells are of a 
mesenchymal origin, showing spindle morphology when adhered on tissue 
culture plastic surfaces (Figure 1). Typical mesenchymal stem cell markers 
CD13, CD90, and CD146 were positive in these cells and were negative for 
hematopoietic stem cell marker CD34 (Figure 2). 
Figure 1. Microscopic images of passage 4 human DPSCs isolated from 
molar teeth. Human dental pulp stem cells were isolated and expanded from 
surgically removed third molar teeth. Their spindle shape morphology was 
confirmed via microscopic observation. Scale bars, 100 μm.
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Figure 2. Expression levels of mesenchymal cell surface markers.
Expression of typical mesenchymal stem cell markers CD13, CD90, and 
CD146 was confirmed via flow cytometry analyses. These cells were negative 
for lymphocytic marker CD34. 
LHX8 is overexpressed using a lentiviral system
Since osteodifferentiation is a long process often take up to 4 weeks in culture, 
I assumed a stable expression of the target gene was necessary for 
osteodifferentiation studies. Therefore, lentiviral vector system was chosen for 
LHX8 gene overexpression in DPSCs (Figure 3). Using the lentiviruses, 
LHX8 protein was overexpressed in DPSCs as confirmed by flow cytometry 
analysis of GFP marker protein (Figure 4) and by antibody detection of LHX8 
protein (Figure 5).
14
Figure 3. Plasmid vectors used in this study. (A) pMD2.G plasmid encodes 
vesicular stomatitis virus glycoprotein which facilitates binding to target cells. 
(B) psPAX2 plasmid encodes a portion of human immunodeficiency virus 
proteins to enable genomic integration of desired sequences. (C) 
pCDH_LHX8 plasmid encodes sequences required for genomic integration 
and expression of LHX8 protein and green fluorescent protein. 
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Figure 4. Lentivirus-mediated overexpression of LHX8 in human DPSCs.
(A) Overexpression of human LHX8 protein was confirmed via flow 
cytometry analyses. Vector-only control cells expressed similar amounts of 
GFP marker proteins. (B) Similar morphology of LHX8 DPSCs and GFP 
control cells. (C) GFP expression levels were observed via fluorescence 
microscopy. (D) LHX8 protein was detected with a specific antibody by 
western blotting. (E) An enlarged version of (D). Scale bars, 100 μm.  
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LHX8 overexpression does not affect proliferation of DPSCs 
To determine the consequences of LHX8 overexpression, the proliferation rate 
of DPSCs were observed. LHX8 overexpressing cells and control cells did not 
show any significant difference in proliferation by WST-1 assay (Figure 5)
Figure 5. Effect of LHX8 overexpression on cell growth. The proliferation 
of DPSCs with and without LHX8 overexpression was compared using WST-
1 assay. Control, empty vector-incorporated control DPSCs. LHX8, LHX8
overexpressed DPSCs.
17
LHX8 overexpression does not affect the migration of DPSCs 
The migrating ability of DPSCs was analyzed by allowing cells to migrate 
through small pores toward chemoattractant. DPSCs with or without LHX8
overexpression did not show any difference in migration when Boyden 
chamber culture system was used (Figure 6A-C). When migration was 
monitored real-time using the Real Time Cell Analyzer (RTCA), LHX8
DPSCs showed marginally attenuated migration but there was no statistical 
significance (Figure 6D). 
Figure 6. Effect of LHX8 overexpression on migration. Migration of 
DPSCs with and without LHX8 overexpression was compared. Crystal violet 
stained migrated (A) control cells and (B) LHX8 cells in the Boyden chamber 
assay. Cells were allowed to migrate through 8 μm-sized pores for 24hours. 
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(C) The relative ratio of migrated cells was quantified by solubilizing crystal 
violet crystals. (D) Migration of DPSCs was recorded real-time using RTCA 
device. Control, empty vector-incorporated control DPSCs. LHX8, LHX8
overexpressed DPSCs.
LHX8 overexpression does not affect the angiogenic ability of DPSCs 
DPSCs are known to possess angiogenic abilities. I sought to examine if 
LHX8 overexpression dysregulates angiogenic potential of DPSCs. The 
results of tube assay using HUVEC cells showed slightly decreased 
angiogenic tube formation in LHX8 overexpressed cells, but without statistical 
significance (Figure 7).  
Figure 7. Effect of LHX8 overexpression on the angiogenic property of 
DPSCs. Human umbilical cord endothelial cell tube formation assay was 
performed. Two-day conditioned media from DPSCs with and without LHX8
overexpression was treated on human umbilical cord endothelial cells layered 
on Matrigel® matrix. Endothelial cell tube formation was observed 
microscopically after 24 hours. The number of tubes was counted from four 
randomly selected images. Control, empty vector-incorporated control DPSCs. 
LHX8, LHX8 overexpressed DPSCs.
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LHX8 overexpression attenuates osteogenic differentiation of DPSCs
The effect of LHX8 overexpression on osteodifferentiation was analyzed with 
various methods. Osteogenic genes were upregulated on osteogenic day 14, 
and the upregulation was attenuated in LHX8 cells (Figure 8). The activity of 
alkaline phosphatase, an enzyme which plays important roles in skeletal 
development, was diminished in LHX8 overexpressing DPSCs (Figure 9). 
Additionally, the amount of calcium accumulation was reduced in LHX8 cells 
(Figure 10).    
Figure 8. Effect of LHX8 overexpression on osteogenic gene expression 
signature. Control DPSCs and LHX8 overexpressing DPSCs were 
osteodifferentiated and RNA was isolated on indicated days. Expression levels 
of osteogenic genes were analyzed by real-time PCR. Control, empty vector-
incorporated control DPSCs. LHX8, LHX8 overexpressed DPSCs. *, P<0.05, 
**, P<0.01
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Figure 9. Effect of LHX8 overexpression on alkaline phosphatase (ALP) 
activity of DPSCs. Control DPSCs and LHX8 overexpressing DPSCs were 
osteodifferentiated for 14 days. ALP activity was measured using BCIP/NBT
method in control (A) and LHX8 (B) cells. (C) Chromogens were solubilized 
with acidic sodium dodecyl sulfate solution for quantification of ALP levels. 
Control, empty vector-incorporated control DPSCs. LHX8, LHX8
overexpressed DPSCs. **, P<0.01
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Figure 10. Effect of LHX8 overexpression on calcification of DPSCs.
Control DPSCs and LHX8 overexpressing DPSCs were osteodifferentiated for 
21 days. Accumulated calcium nodules were stained with alizarin red S (ARS) 
in control (A) and LHX8 (B) cells. (C) Calcium levels were quantified by 
solubilizing calcium nodules with acidic sodium dodecyl sulfate solution. 
Control, empty vector-incorporated control DPSCs. LHX8, LHX8
overexpressed DPSCs. **, P<0.01
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DISCUSSION
DPSCs have been successfully isolated from human third molars and were 
expanded in vitro. These cells showed typical MSC morphology and 
expressed MSC surface marker proteins. LHX8 was overexpressed in these 
cells using the lentiviral vector system. Expression of LHX8 was confirmed by 
flow cytometric analysis of co-expression of the fluorescent marker protein 
and direct detection of LHX8 by the western blot. The consequences of LHX8
overexpression was analyzed regarding cell proliferation, migration, 
angiogenic property, and osteodifferentiation property. Among these portraits 
tested, osteodifferentiation ability was attenuated in LHX8 DPSCs and the 
results were visualized by real-time PCR analyses of relevant genes, ALP 
activity measurement, and calcium accumulation measurement. 
Previous reports of LHX8, mostly animal studies, suggested a role of 
the gene in osteogenesis, and my results provided that the role of the gene is 
inhibitory in a human cell model. A study demonstrated that siRNA-mediated 
knockdown of LHX8 lead to increased ALP activities and calcium nodule 
formation [11]. 
There are chances that suppression of osteodifferentiation by LHX8
may lead to enhancement of other cellular functions. I have searched for 
consequences of LHX8 overexpression on cells, and unfortunately, no 
difference was observed regarding proliferation, migration, angiogenic 
abilities of DPSCs. Angiogenic properties are known to be strengthened 
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during the process of osteodifferentiation [12]. Since LHX8 attenuates 
osteodifferentiation, the gene may also reduce the angiogenic potential in cells. 
The angiogenic tube assay results showed that the reduction in tube formation 
was marginally observed in LHX8 cells, but was not with a statistical 
significance. A stronger and longer stimulation with the osteogenic condition 
may clarify this issue.
In summary, a LHX8 overexpressing DPSC model has been 
successfully constructed. The cell model showed that LHX8 plays an 
inhibitory role in osteogenesis. Other portraits, such as proliferation, 
migration, and angiogenic property, were not significantly changed. 
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PART 2
Inhibition of LHX8 overexpression-
associated ID1 in human dental pulp stem 
cells
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INTRODUCTION
Craniofacial bone defects caused by osteomyelitis, malignancy or 
traumatic conditions require bone reconstruction [13, 14]. Autologous bone 
grafting is the traditional approach for reconstruction [15]. However, 
increased surgical costs, pain due to invasive procedures, graft infection, and 
graft resorption are shortcomings of present bone grafting procedures [16]. 
Most importantly, available autologous bone is inherently limited by nature 
[17]. Recent advances in technology lead to the development of bone graft 
substitutes, stem cell therapies, osteogenic agents, or a combination of all, 
which may be beneficial in addressing the problem [17]. Among osteogenic 
agents, bone morphogenic proteins (BMPs), are often used in clinics to aid 
bone reconstruction. However, adverse side-effects associated with its use has 
been well-described and being a recombinant protein its high cost blocks 
BMPs to be widely used [18, 19]. There are attempts to develop chemical 
agents as alternatives to BMPs, but results are still preliminary. There is an 
urgent need for the development of osteogenic agents which may aid bone 
regeneration.
In this study, cDNA microarray was performed on control DPSCs 
and LHX8 overexpressed DPSCs. The characteristics of differentially 
expressed genes were analyzed. The osteogenic genes which were also 
associated with LHX8 overexpression were screened, and chemical inhibitors 
or neutralizing antibodies for their protein products were treated to see if these 
genes are indeed functional in osteogenesis.  
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        MATERIALS AND METHODS
1. Cell culture
The generations of LHX8 overexpressing DPSCs and control DPSCs have 
been described in Part 1. These cells were cultured in the aMEM 
supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin, and 100 
mg/mL streptomycin and incubated at 37°C in 5% CO2. The medium was 
changed every 3-4 days. All primary cells used in this study were in passages
2-5. 
2. cDNA microarray
DPSCs were osteodifferentiated for 4 days and total RNA was extracted as 
described above. cDNA microarray was performed with GeneChip® Human 
Gene 2.0 ST Array. cDNA was synthesized using the GeneChip Whole 
Transcript (WT) Amplification kit as described by the manufacturer. The 
sense cDNA was then fragmented and biotin-labeled with terminal 
deoxynucleotidyl transferase (TdT) using the GeneChip WT Terminal 
Labeling Kit. Approximately 5.5 μg of labeled DNA target was hybridized to 
the Affymetrix GeneChip Array at 45°C for 16 hours. Hybridized arrays were 
washed and stained on a GeneChip Fluidics Station 450 and scanned on a 
GCS3000 Scanner (all from Affymetrix, Santa Clara, CA, USA). Array data 
export processing and analysis were performed using Affymetrix® GeneChip 
Command Console® Software, Affymetrix Power Tools and R 3.1.2 
(https://www.r-project.org/).
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3. Transcriptomic data analyses
Gene ontology analysis was performed by the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 
version 6.8, which is developed by National Institutes of Health (Bethesda, 
MD, USA). 
4. Statistical analysis
Statistical analysis was performed using Prism software (GraphPad Software, 
San Diego, CA, USA). Comparison between two groups was made with 
Student’s t-test. Significance was defined as P≤0.05. Values in each graph 
represent mean±standard deviation. All assays were performed at least thrice 
and representative data are presented.
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RESULTS
LHX8 overexpression regulated expression levels of diverse genes
To study transcriptional aberrations due to LHX8 overexpression, cDNA 
microarray was performed on LHX8 and control DPSCs. LHX8
overexpression lead to 716 differentially expressed genes (DEGs) and top 20 
upregulated and top 20 downregulated DEGs are listed in Tables 1 and 2, 
respectively. DEGs are defined as genes whose absolute fold changes were 
above 1.5 with a statistical significance (P<0.05). 
Osteodifferentiation of DPSCs regulated expression levels of diverse 
genes
Osteodifferentiation modulates the expression of a multitude of genes, and the 
osteogenic stimulus resulted in 345 DEGs in the control DPSCs versus 
undifferentiated. Top 20 upregulated and top 20 downregulated DEGs are 
listed in Tables 3 and 4, respectively. cDNA microarray was performed on 
osteodifferentiation day 4. 
29
Table 1. Top 20 upregulated genes in LHX8 overexpressing DPSCs
compared to control DPSCs






















Table 2. Top 20 downregulated genes in LHX8 overexpressing DPSCs 
compared to control DPSCs






















Table 3. Top 20 upregulated genes in day 4 osteodifferentiated DPSCs 
compared to undifferentiated DPSCs






















Table 4. Top 20 downregulated genes in day 4 osteodifferentiated DPSCs 
compared to undifferentiated DPSCs






















To achieve a more comprehensive genome-wide understanding, gene 
ontology terms associated with DEGs were analyzed. The gene ontology 
analysis showed that osteogenic stimulus of control DPSCs lead to 
dysregulation of DEGs related to the binding function of the cell, especially 
protein binding (Figure 1). Interestingly, LHX8-associated DEGs were also 
related to the binding function of the cell, implying possible involvement of 
LHX8 in osteodifferentiation (Figure 2).
Figure 1. Gene ontology terms associated with osteodifferentiation of 
DPSCs. Top ten gene ontology terms in the molecular function category 
which were dysregulated during osteodifferentiation in control DPSCs were 
listed. ***. P<001. 
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Figure 2. Gene ontology terms associated with LHX8 overexpression of 
DPSCs. Top ten gene ontology terms in the molecular function category 
which were dysregulated by LHX8 overexpression in DPSCs were listed. ***. 
P<001. 
LHX8 regulates osteogenic genes in an opposite way when compared with 
control DPSCs.
When a comparison was made with undifferentiated DPSCs, the number of 
osteodifferentiation associated DEGs were 345 in control DPSCs and 53 in 
LHX8 DPSCs, showing LHX8 DPSCs were less responsive to 
osteodifferentiation stimulus. The majority (38/53, 71.7%) of DEGs in LHX8
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DPSCs that were responsive to osteodifferentiation were also DEGs of control 
DPSCs (Figure 3). When the 38 common DEGs which were associated with 
osteodifferentiation both in control and LHX8 DPSCs were depicted as a 
heatmap, the genes were grouped into two separate clusters (Figure 4). One 
cluster (Cluster A) were genes with decreased mRNA expression during 
osteodifferentiation in control DPSCs and with increased mRNA expression 
in LHX8 cells, and the other cluster the opposite (Cluster B). Therefore, it can 
be concluded that the role of LHX8 during the osteodifferentiation process of 
DPSCs may be inhibitory, supporting findings in previous functional studies.
Figure 3. Osteodifferentiation associated DEGs. The number of DEGs in 
response to osteodifferentiation stimulus was counted in control and LHX8
DPSCs. DEG, differentially expressed genes.
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Figure 4. Heatmap of osteodifferentiation DEGs common in control and 
LHX8 DPSCs. The 38 genes which were common osteogenic DEGs both in 
control and LHX8 DPSCs were clustered and the expression levels were 
depicted as a heatmap. The Row z-score is calculated as the following: 
(expression – mean expression) / standard deviation.
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LHX8-associated DEGs upon osteodifferentiation
Upon osteodifferentiation, LHX8 overexpression resulted in 427 DEGs. These 
are also associated with gene ontology term of protein binding (data not 
shown). Top 20 upregulated and top 20 downregulated DEGs are listed in 
Tables 5 and 6, respectively. 
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Table 5. Top 20 upregulated genes in LHX8 DPSCs compared to control 
DPSCs when osteodifferentiated






















Table 6. Top 20 downregulated genes in LHX8 DPSCs compared to
control DPSCs when osteodifferentiated






















Inhibition of LHX8-associated protein ID1 by a small molecule results in 
increased osteogenesis.
The anti-osteogenic role of LHX8 has been partly demonstrated in Part 1 of 
this study, by in vitro functional experiments. Confirmation of these results by 
functional blockage of LHX8 with a small molecule is unfortunately 
impossible since no chemical inhibitor targeting LHX8 protein has been 
developed to my knowledge. I assumed that inhibition of LHX8-associated 
proteins may result in altered osteodifferentiation of DPSCs. From those top 
20 genes whose expression has been downregulated during 
osteodifferentiation in control DPSCs (Table 4), target genes were selected 
with these following criteria: i) decreased expression in control DPSCs during 
osteodifferentiation, ii) increased expression in LHX8 DPSCs during 
osteodifferentiation, iii) availability of chemical inhibitor or a neutralizing 
antibody. Five potential target genes were chosen: DCLK1, CXCL14, 
MAP2K6, ID1, and EGR1. The neutralizing antibodies or chemical inhibitors
for IL11 and MMP3 have been developed, but were not tested in this study 
due to commercial availability at the time of experiments (Table 7). Inhibitor 
information of these target genes is summarized in Table 8. Among the 
inhibitors tested, ML323, targeting ID1, resulted in an increased 
osteodifferentiation of DPSCs shown by increased ALP activity and increased 
calcium accumulation (Figure 4).
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Table 7. LHX8-associated genes with potential role in osteogenesis







EGR1 NM_001964 -2.8 2.28 Yes
LRRC15 NM_001135057 -2.76 4.17
CLSTN2 NM_022131 -2.66 5.56
ID1 NM_002165 -2.64 1.78 Yes
MMP3 NM_002422 -2.52 1.49 Yes a
IL11 NM_000641 -2.44 1.32 Yes a
FAM72D NM_207418 -2.34 1.19
ITGA2 NM_002203 -2.3 2.64
IER3 NM_003897 -2.29 1.86
HIST1H3G NM_003534 -2.24 1.08
MAP2K6 NM_002758 -2.21 2.56 Yes
CXCL14 NM_004887 -2.2 8.23 Yes
APCDD1L NM_001304787 -2.1 1.46
KRTAP2-3 NM_001165252 -2.09 1.34
HIST1H1B NM_005322 -2.09 1.14
FST NM_006350 -2.06 1.97
HIST1H2AI NM_003509 -2.05 1.03
TRIB1 NM_001282985 -2.04 1.47
CDCP1 NM_022842 -2.04 2.41
DCLK1 NM_001195415 -2.01 3.88 Yes
a not included in the study due to commercial availability limitations  
Abbreviations: CD, control DPSCs osteodifferentiated; CO, control DPSCs undifferentiated; 
LD, LHX8 DPSCs osteodifferentiated
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Table 8. Chemical inhibitors and neutralizing antibodies tested.
Compound Name Protein Target
Gene 
Target
Concentration Cat. No. References
LRRK2-IN-1 Doublecortin like kinase 1 DCLK1 10 μM TOCRIS 4273 [20]
CXCL14 neutralizing 
antibody
CXC motif chemokine 
ligand 14 




MAP2K6 10 μM Sigma SML1083 [22]
ML323
Inhibitor of DNA 
binding 1




EGR1 10 nM Sigma M6891 [25]
Figure 5. ML323 enhances the osteogenic function of DPSCs. (A) 
Alkaline phosphatase (ALP) activity of DPSCs on day 14 of 
osteodifferentiation with various compounds. (B) Accumulated calcium 
staining by alizarin red S (ARS) on day 21. Control, empty vector-
incorporated control DPSCs. LHX8, LHX8 overexpressed DPSCs. neut ab, 
neutralizing antibody. **, P<0.01
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DISCUSSION
Transcriptomic analyses were performed on LHX8 overexpressing DPSCs 
and control DPSCs. cDNA microarray data supported the finding in Part 1 
that LHX8 plays an osteo-inhibitory role. For the genes which were associated 
with both osteodifferentiation and LHX8 overexpression, chemical inhibitors 
or neutralizing antibodies were treated to their protein products to confirm 
their functional role in osteogenesis. 
The microarray results showed differential expression of 716 genes 
in LHX8 overexpressed DPSCs compared to control DPSCs, and these genes 
were mostly associated with the binding function of the cell. When DPSCs 
were osteodifferentiated, 345 genes were differentially expressed compared to 
control DPSCs. These genes were also associated with binding, implying the 
involvement of LHX8 in osteodifferentiation. Interestingly, a smaller number 
of genes (n=53) were differentially expressed during the osteodifferentiation 
process in LHX8 DPSCs, partially supporting the attenuated response of 
LHX8 overexpressed DPSCs to osteogenic stimulus. The common 
osteodifferentiation-associated DEGs of control DPSCs and LHX8 DPSCs 
were clearly clustered into two groups: when a cluster of genes was 
downregulated by osteodifferentiation signal, the same genes were 
upregulated by LHX8 and vice versa. This also supports the anti-osteogenic 
role of LHX8.
Dental mesenchyme, where LHX8 is strongly expressed during the 
course of embryonic development, goes through the condensation process 
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[26]. Gene products regulating protein binding may play important roles 
during mesenchymal condensation. Therefore, the role of binding function 
genes which were dysregulated by LHX8 needs to be elucidated. It is a pity 
that there is no mesenchyme condensation cell model available to my 
knowledge.
Microarray analyses were performed on the fourth day of 
osteodifferentiation, which is a relatively early time point taking into an 
account that osteodifferentiation is a long process often taking weeks [27]. I 
assumed that LHX8 may play a role at the early stage of craniofacial tissue 
development considering the precedent reports that LHX8 is expressed from
embryonic day 9.5 [28]. Therefore cDNA array comparisons were made 
before full osteogenic signals were activated. My real-time PCR results 
showed some osteogenic genes were even not fully activated on 
osteodifferentiation day 7, suggesting that DEGs in my microarray results are 
indeed early response genes. A thorough comparison of early response genes 
and late response genes during the course of osteodifferentiation is also an 
interesting topic to commence further studies.
There is no chemical inhibitor for LHX8 protein, however, and this 
limits the clinical utility of the finding. I have used transcriptomic analysis to 
discover LHX8-associated genes which are functional during the process of 
osteogenesis. Among the LHX8-regulated osteogenic genes, ID1 showed an 
anti-osteogenic role which was proven by the small molecule inhibitor 
treatment. ID1 is an oncogenic protein that is normally poly-ubiquitinated and 
rapidly degraded in the normal condition [29]. An ubiquitin-specific protease 
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USP1 deubiquitinates ID1 and rescues it from proteasome degradation [24]. 
Blockage of USP1 function leads to subsequent degradation of ID1 [24]. My 
results show that ML323, an inhibitor of USP1, enhances osteodifferentiation 
of DPSCs possibly by suppressing USP1-mediated deubiquitination of ID1 
[30]. A more in-depth study has to be performed to discover clinically 
adaptable small molecule osteogenic agents, possibly by using chemical 
libraries of FDA-approved drugs [31].  
In summary, LHX8 overexpression showed anti-osteogenic effects on 
DPSCs. Chemical inhibitor studies for LHX8 downstream genes confirmed 
that treatment of ML323 during osteodifferentiation lead to enhanced 
osteogenesis. These results may provide clinical insights which may lead to 
the development of osteogenic agents.   
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국문 초록
전사인자 단백질을 발현하는 LIM homeobox 8 (LHX8) 유전자
는 두개부의 치아 및 골조직 배아발달 단계에서 중요한 역할을 한
다. 그러나 골 분화능을 가진 인간 치수줄기세포의 골분화에 있어서
LHX8의 역할은 명확하지 않다. 본 연구는 렌티바이러스 시스템을
활용하여 인간치수줄기세포에서 LHX8를 과발현시키고, 과발현된
LHX8이 골분화에 미치는 영향을 연구하였다. LHX8 과발현은 세포의
성장속도, 이동속도, 혈관형성능에 영향이 없었다. 반면 골분화는
LHX8 과발현 모델에서 억제되었는데 염기성인산분해효소 활성의 감
소 및 칼슘 축적량 감소를 통해 확인되었다. cDNA 마이크로어레이
분석을 시행한 결과 골분화 유도시 치수줄기세포에서 단백질결합에
관계된 유전자군에 유의한 변화가 있었다. 골분화 유도와 골분화를
억제하는 LHX8 과발현에 의해 공통적으로 발현양이 변화한 유전자
는 총 38개였는데 2개의 유전자군으로 구별되었다. 각 군의 유전자
는 골분화 유도에 의해 발현이 증가할 때 LHX8 과발현에 의해 감소
하거나 혹은 그 반대의 경우로서 LHX8의 골분화 억제능을 재확인할
수 있는 결과였다. 다음은 치수줄기세포의 골분화를 촉진할 수 있는
분자적 방법을 찾기 위해서 LHX8 과발현 없는 골분화 조건에서는
발현이 감소하지만 골분화를 억제하는 LHX8 과발현 조건에서 골분
화 유도시에는 발현이 증가하는 유전자를 도출하였다. 도출된 유전
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자는 각 유전자가 발현하는 단백질에 대한 화학적 저해제를 처리한
후 골분화가 촉진되는지 살펴보았다. ID1 발현 단백질인 DNA-
binding protein inhibitor ID-1 활성을 억제하는 화학적 저해제 ML323
에 의해 치수줄기세포의 골분화가 촉진되었다. 이로서 본 연구는
LHX8 과발현 인간 치수유래 줄기세포 모델을 활용하여 LHX8가 인
간 치수유래 줄기세포의 골분화를 억제함을 밝혔으며 골분화 억제
유전자 ID1을 발굴하였고 DNA-binding protein inhibitor ID-1을 억제함
으로써 인간 치수줄기세포의 골분화능을 촉진할 수 있음을 보여주
었다.
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